119 related articles for article (PubMed ID: 34784418)
1. FOXC1.
Li M; Lv H; Zhong S; Zhou S; Lu H; Yang W
Arch Pathol Lab Med; 2022 Aug; 146(8):994-1003. PubMed ID: 34784418
[TBL] [Abstract][Full Text] [Related]
2. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
[TBL] [Abstract][Full Text] [Related]
3. The role of FOXC1/FOXCUT/DANCR axis in triple negative breast cancer: a bioinformatics and experimental approach.
Kamaliyan Z; Mirfakhraie R; Azizi-Tabesh G; Darbeheshti F; Omranipour R; Ahmadinejad N; Zokaei E; Yassaee VR
Mol Biol Rep; 2022 Apr; 49(4):2821-2829. PubMed ID: 35066769
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers.
Kim S; Moon BI; Lim W; Park S; Cho MS; Sung SH
Clin Breast Cancer; 2018 Oct; 18(5):e1123-e1132. PubMed ID: 29754847
[TBL] [Abstract][Full Text] [Related]
5. Subclassifying triple-negative breast cancers and its potential clinical utility.
Lian J; Ma HX; Xu EW; Bu P; Yun KM; Xi YF
Virchows Arch; 2022 Jul; 481(1):13-21. PubMed ID: 35471664
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis of Basal-Like Breast Cancer Using a FOXC1-Based Assay.
Jensen TW; Ray T; Wang J; Li X; Naritoku WY; Han B; Bellafiore F; Bagaria SP; Qu A; Cui X; Taylor CR; Ray PS
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26041837
[TBL] [Abstract][Full Text] [Related]
7. FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer.
Xu YL; Yao R; Li J; Zhou YD; Mao F; Pan B; Sun Q
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1205-1213. PubMed ID: 28493031
[TBL] [Abstract][Full Text] [Related]
8. Subtyping of triple-negative breast cancers: its prognostication and implications in diagnosis of breast origin.
Hu H; Tong K; Tsang JY; Ko CW; Tam F; Loong TC; Tse GM
ESMO Open; 2024 Apr; 9(4):102993. PubMed ID: 38613910
[TBL] [Abstract][Full Text] [Related]
9. Forkhead box C1 boosts triple-negative breast cancer metastasis through activating the transcription of chemokine receptor-4.
Pan H; Peng Z; Lin J; Ren X; Zhang G; Cui Y
Cancer Sci; 2018 Dec; 109(12):3794-3804. PubMed ID: 30290049
[TBL] [Abstract][Full Text] [Related]
10. FOXC1-induced non-canonical WNT5A-MMP7 signaling regulates invasiveness in triple-negative breast cancer.
Han B; Zhou B; Qu Y; Gao B; Xu Y; Chung S; Tanaka H; Yang W; Giuliano AE; Cui X
Oncogene; 2018 Mar; 37(10):1399-1408. PubMed ID: 29249801
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal regulation of forkhead box C1 and L1 cell adhesion molecule contributes to triple-negative breast cancer progression.
Zhang F; Xu Y; Lin J; Pan H; Giuliano AE; Cui X; Cui Y
Breast Cancer Res Treat; 2024 Apr; 204(3):465-474. PubMed ID: 38183514
[TBL] [Abstract][Full Text] [Related]
12. Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.
Liu Y; Teng L; Fu S; Wang G; Li Z; Ding C; Wang H; Bi L
BMC Cancer; 2021 May; 21(1):644. PubMed ID: 34053447
[TBL] [Abstract][Full Text] [Related]
13. [Triple-negative breast cancer : Classification, current concepts, and therapy-related factors].
Sinn HP; Varga Z
Pathologie (Heidelb); 2023 Feb; 44(1):32-38. PubMed ID: 36595080
[TBL] [Abstract][Full Text] [Related]
14. EZH2 regulates expression of FOXC1 by mediating H3K27me3 in breast cancers.
Zheng XJ; Li W; Yi J; Liu JY; Ren LW; Zhu XM; Liu SW; Wang JH; Du GH
Acta Pharmacol Sin; 2021 Jul; 42(7):1171-1179. PubMed ID: 33057161
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemistry-based molecular subtyping of triple-negative breast cancer and its prognostic significance.
Leeha M; Kanokwiroon K; Laohawiriyakamol S; Thongsuksai P
Pathol Oncol Res; 2023; 29():1611162. PubMed ID: 37274773
[No Abstract] [Full Text] [Related]
16. Basal-like breast cancer defined by FOXC1 expression offers superior prognostic value: a retrospective immunohistochemical study.
Ray PS; Bagaria SP; Wang J; Shamonki JM; Ye X; Sim MS; Steen S; Qu Y; Cui X; Giuliano AE
Ann Surg Oncol; 2011 Dec; 18(13):3839-47. PubMed ID: 21424368
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic features and prognoses of different histologic types of triple-negative breast cancer: A large population-based analysis.
Zhao S; Ma D; Xiao Y; Jiang YZ; Shao ZM
Eur J Surg Oncol; 2018 Apr; 44(4):420-428. PubMed ID: 29429597
[TBL] [Abstract][Full Text] [Related]
18. Metaplastic carcinoma show different expression pattern of YAP compared to triple-negative breast cancer.
Min Kim H; Kim SK; Jung WH; Koo JS
Tumour Biol; 2015 Feb; 36(2):1207-12. PubMed ID: 25344213
[TBL] [Abstract][Full Text] [Related]
19. Triple Negative Breast Cancer Detection Using LC-MS/MS Lipidomic Profiling.
Eghlimi R; Shi X; Hrovat J; Xi B; Gu H
J Proteome Res; 2020 Jun; 19(6):2367-2378. PubMed ID: 32397718
[TBL] [Abstract][Full Text] [Related]
20. FOXC1 is associated with estrogen receptor alpha and affects sensitivity of tamoxifen treatment in breast cancer.
Wang J; Xu Y; Li L; Wang L; Yao R; Sun Q; Du G
Cancer Med; 2017 Jan; 6(1):275-287. PubMed ID: 28028927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
